Current concepts and review of pimecrolimus in the treatment of psoriasis.
The ascomycine macrolactam derivative pimecrolimus has a gene profile of broad anti-inflammatory activity without evidence of toxicity. It exhibits excellent clinical tolerability after 4 weeks and 12 weeks, respectively, of oral treatment, and it is highly effective in a concentration-dependent manner in patients with moderate to severe plaque psoriasis. Although not yet approved, oral pimecrolimus promises to be a novel, highly effective, and well-tolerated drug in the systemic treatment of psoriasis and other T-cell-mediated skin diseases.